Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 5000
Summary
- Conditions
- Metastatic Non-small Cell Lung Cancer (NSCLC)
- Non Small Cell Lung Cancer (Stage III)
- Non Small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Stage II
- Small Cell Lung Cancer
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and outcome of unselected patients in real-life practice, is crucial to evaluate and improve the quality of care for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The purpos...
Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and outcome of unselected patients in real-life practice, is crucial to evaluate and improve the quality of care for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The purpose of CRISP is to set up a national clinical research platform to document uniform data on the molecular testing, treatment, course of disease in patients with NSCLC or SCLC. A particular focus is on molecular biomarker testing before the start of first-line treatment of patients with advanced or metastatic NSCLC. The data shall be used to assess the current state of care and to develop recommendations concerning topics that could be improved. PRO assessment will provide large-scale data on quality of life and anxiety/depression for real-life patients with NSCLC or SCLC in routine practice. In addition, two questionnaires (concerning individual quality of life and patient-caregiver communication) will be validated in German patients with metastatic NSCLC. Furthermore, CRISP will set up a decentralized clinically annotated tissue repository for future collaborative, investigational scientific biomarker testing.
Tracking Information
- NCT #
- NCT02622581
- Collaborators
- AstraZeneca
- Celgene Corporation
- Merck Sharp & Dohme Corp.
- Amgen
- Novartis Pharmaceuticals
- Pfizer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- iOMEDICO AG
- Janssen-Cilag GmbH
- Eli Lilly and Company
- Roche Pharma AG
- Takeda
- Investigators
- Principal Investigator: Frank Griesinger, Prof. Dr. Pius-Hospital Oldenburg